Federal Circuit Rules for The Medicines Company in Angiomax(R) (bivalirudin) Patent Litigation

PARSIPPANY, N.J.--(Healthcare Sales & Marketing Network)--The Medicines Company announced that the U.S. Court of Appeals for the Federal Circuit Court, in an en banc review, unanimously affirmed the earlier district court ruling in The Medicines Company v.... Biopharmaceuticals, Cardiology, LitigationThe Medicines Company, Angiomax, bivalirudin, Hospira
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news